The US Food and Drug Administration has approved Journavx, also known as suzetrigine 50 milligram oral tablets—a first-in-class non-opioid analgesic—to treat moderate to severe acute pain in adults.
In an international effort, researchers at Western University, the University of Maryland School of Dentistry (UMSOD) and Neuroscience Research Australia (NeuRA) uncovered how specific patterns in ...